Patent · US Active

Oligonucleotide compounds for targeting huntingtin mRNA

US11230713B2 · kind B2 · utility

13Cited by
28References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 6, 2020
Grant dateJan 25, 2022
Priority date—
Expiry dateMar 6, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/51
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.